Professor Michael Murray

Pharmacology, School of Medical Sciences

K25 - Medical Foundation Building
The University of Sydney
NSW 2006 Australia

T: +61 2 9351 2326; MFB +61 2 9036 3259
F: +61 2 9351 6950; MFB +61 2 9351 4447

Biographical details

Michael Murray graduated with a Bachelor of Pharmacy with First Class Honours and a PhD in Pharmaceutical Chemistry from the University of Sydney. After undertaking postdoctoral research with CF Wilkinson in the Institute for Comparative and Environmental Toxicology at Cornell University, Ithaca, NY he returned to Westmead Hospital and was appointed as an HMRC Research Fellow in 1987, promoted to NHMRC Senior Research Fellow in 1989 and to NHMRC Principal Research Fellow in 1994. In 1995 he received a DSc from The University of Sydney. After 5 years at UNSW in The School of Physiology and Pharmacology, he returned in July, 2003 to the University of Sydney's Faculty of Pharmacy to take up the inaugural Chair of Pharmacogenomics. The Pharmacogenomics and Drug Development research laboratory is located in the Faculty's new laboratories in the Medical Foundation Building. [More...]

Research interests

Human drug metabolism

Cytochrome P450 (CYP) pharmacogenetics

CYP regulation by drugs, nutrients and endobiotics

Adverse drug reactions caused by reactive drug metabolites

Drug-drug interactions due to inhibition of P450 enzymes

Current national competitive grants*


Novel cellular trafficking mechanisms for the drug influx transporter, human Organic Anion Transporting Polypeptide 1a2 (Oatp1a2)
Zhou F, Murray M
NHMRC Project Grants ($326,175 over 3 years)

Pharmacological development of synthetic analogues of cytochrome P450-mediated omega-3 fatty acid epoxides as novel anti-metastatic agents
Murray M, Duke C, Cui S, Ching L, Dunstan C
NHMRC Project Grants ($835,860 over 3 years)

* Grants administered through the University of Sydney


Pharmaceutical Sciences; Cancer


2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009


  • Chan, T., Zheng, J., Zhu, L., Grewal, T., Murray, M., Zhou, F. (2015), Putative Transmembrane Domain 6 of the Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2) Influences Transporter Substrate Binding, Protein Trafficking, and Quality Control. Molecular Pharmaceutics. 12(1), 111-119. [Abstract]


  • Toh, D., Limenta, L., Yee, J., Wang, L., Goh, B., Murray, M., Lee, E. (2014), Effect of Mushroom Diet on Pharmacokinetics of Gabapentin in Healthy Chinese Subjects. British Journal of Clinical Pharmacology. 78(1), 129-134. [Abstract]
  • Murray, M., Dyari, H., Allison, S., Rawling, T. (2014), Lipid analogues as potential drugs for the regulation of mitochondrial cell death. British Journal of Pharmacology. 171(8), 2051-2066. [Abstract]
  • Dyari, H., Rawling, T., Bourget, K., Murray, M. (2014), Synthetic W-3 Epoxyfatty Acids As Antiproliferative and Pro-apoptotic Agents in Human Breast Cancer Cells. Journal of Medicinal Chemistry. 57(17), 7459-7464. [Abstract]
  • Johnston, R., Rawling, T., Chan, T., Zhou, F., Murray, M. (2014), Selective Inhibition of Human Solute Carrier Transporters by Multikinase Inhibitors. Drug Metabolism and Disposition. 42(11), 851-857. [Abstract]
  • Gu, R., Hibbs, D., Ong, J., Edwards, R., Murray, M. (2014), The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2. Biochemical Pharmacology. 88(2), 245-252. [Abstract]
  • Zheng, J., Chan, T., Cheung, F., Zhu, L., Murray, M., Zhou, F. (2014), PDZK1 and NHERF1 regulate the function of human organic anion transporting polypeptide 1A2 (OATP1A2) by modulating its subcellular trafficking and stability. PloS One. 9(4), e94712. [Abstract]
  • Murray, M. (2014), w-3 polyunsaturated fatty acids and their metabolites as inhibitors of mammalian tumorigenesis. Phytochemistry Reviews. 13(1), 139-156.


  • Zhou, F., Zheng, J., Zhu, L., Jodal, A., Cui, P., Wong, M., Gurney, H., Church, W., Murray, M. (2013), Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2. The AAPS Journal. 15(4), 1099-1108. [Abstract]
  • Cui, P., Rawling, T., Gillani, T., Bourget, K., Wang, X., Zhou, F., Murray, M. (2013), Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells. Biochemical Pharmacology. 86(3), 419-427. [Abstract]
  • Toh, D., Cheung, F., Murray, M., Pern, T., Lee, E., Zhou, F. (2013), Functional Analysis of Novel Variants in the Organic Cation/Ergothioneine Transporter 1 Identified in Singapore Populations. Molecular Pharmaceutics. 10(7), 2509-2516. [Abstract]
  • Ghassabian, S., Murray, M. (2013), Simultaneous In Vivo Phenotyping of CYP Enzymes. In: Methods in Molecular Biology: Cytochrome P450 Protocols. (pp.261-268).United States: Springer Science +Business Media.


  • Cui, P., Rawling, T., Bourget, K., Kim, T., Duke, C., Doddareddy, M., Hibbs, D., Zhou, F., Tattam, B., Petrovic, N., Murray, M. (2012), Antiproliferative and Antimigratory Actions of Synthetic Long Chain n-3 Monounsaturated Fatty Acids in Breast Cancer Cells That Overexpress Cyclooxygenase-2. Journal of Medicinal Chemistry. 55(16), 7163-7172. [Abstract]
  • Murray, M. (2012), Toxicological actions of plant-derived and anthropogenic methylenedioxyphenyl-substituted chemicals in mammals and insects. Journal of Toxicology and Environmental Health. Part B, Critical Reviews. 15(6), 365-395. [Abstract]
  • Ghassabian, S., Rawling, T., Zhou, F., Doddareddy, M., Tattam, B., Hibbs, D., Edwards, R., Cui, P., Murray, M. (2012), Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochemical Pharmacology. 84(2), 215-223. [Abstract]
  • Armour, C., Chaar, B., Murray, M., Ambler, G., Krass, I. (2012), Current therapies and pharmacy programs for obesity and diabetes. In: A Modern Epidemic. (pp.315-338).Australia: Sydney University Press.
  • Rawling, T., McDonagh, A., Tattam, B., Murray, M. (2012), Synthesis of unsymmetrical biaryl ureas from N-carbamoylimidazoles: kinetics and application. Tetrahedron. 68(30), 6065-6070.


  • Toh, D., Murray, M., Pern, T., Mulay, V., Grewal, T., Lee, E., Zhou, F. (2011), Functional analysis of pharmacogenetic variants of human organic cation/carnitine transporter 2 (hOCTN2) identified in Singaporean populations. Biochemical pharmacology. 82(11), 1692-9. [Abstract]
  • Zhou, F., Lee, A., Krafczyk, K., Zhu, L., Murray, M. (2011), Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. British journal of pharmacology. 162(6), 1380-8. [Abstract]
  • Cui, P., Petrovic, N., Murray, M. (2011), The ω-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 downregulation. British journal of pharmacology. 162(5), 1143-55. [Abstract]


  • Murray, M., Cui, P., Zhou, F. (2010), Roles of Mitogen-Activated Protein Kinases in the Regulation of CYP Genes. Current Drug Metabolism. 11(10), 850-858. [Abstract]
  • Nebot, N., Crettol, S., d'Esposito, F., Tattam, B., Hibbs, D., Murray, M. (2010), Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. British Journal of Pharmacology. 161(5), 1059-1069. [Abstract]
  • Ghassabian, S., Chetty, M., Tattam, B., Glen, J., Rahme, J., Stankovic, Z., Ramzan, I., Murray, M., McLachlan, A. (2010), The participation of cytochrome P450 3A4 in clozapine biotransformation is detected in people with schizophrenia by high-throughput in vivo phenotyping. Journal of clinical psychopharmacology. , 629-631. [Abstract]
  • d'Esposito, F., Nebot, N., Edwards, R., Murray, M. (2010), Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease. British Journal of Clinical Pharmacology. 70(3), 400-408. [Abstract]
  • Rong, X., Li, Y., Ebihara, K., Zhao, M., Kusakabe, T., Tomita, T., Murray, M., Nakao, K. (2010), Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia. British journal of pharmacology. 160(7), 17961807. [Abstract]
  • Lee, A., Murray, M. (2010), Upregulation of human CYP2J2 in HepG2 cells by butylated hydroxyanisole is mediated by c-Jun and Nrf2. Molecular pharmacology. 77(6), 987-94. [Abstract]
  • Rong, X., Li, Y., Ebihara, K., Zhao, M., Naowaboot, J., Kusakabe, T., Kuwahara, K., Murray, M., Nakao, K. (2010), Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia. 53, 1727–1731. [Abstract]
  • Cui, P., Lee, A., Zhou, F., Murray, M. (2010), Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrative stress. British journal of pharmacology. 159(7), 1440-1449. [Abstract]
  • Li, Y., Saito, Y., Kuwahara, K., Rong, X., Kishimoto, I., Harada, M., Horiuchi, M., Murray, M., Nakao, K. (2010), Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. British Journal of Pharmacology. 159(5), 1133-1142. [Abstract]
  • Rawling, T., Duke, C., Cui, P., Murray, M. (2010), Facile and stereoselective synthesis of (Z)-15-octadecenoic acid and (Z)-16-nonadecenoic acid: monounsaturated omega-3 fatty acids. Lipids. 45(2), 159-165. [Abstract]
  • Crettol, S., Petrovic, N., Murray, M. (2010), Pharmacogenetics of phase I and phase II drug metabolism. Current Pharmaceutical Design. 16(2), 204-219. [Abstract]
  • Murray, M. (2010), Cytochromes P450: Roles in the Biotransformation of Chemicals in Cigarette Smoke and Impact of Smoking Cessation on Concurrent Drug Therapy. Journal of Smoking Cessation. 5(2), 107-114.
  • Zhou, F., Zhu, L., Cui, P., Church, W., Murray, M. (2010), Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). British journal of pharmacology. 159(2), 419-27. [Abstract]
  • Petrovic, N., Murray, M. (2010), Using N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD) to assay cyclooxygenase activity in vitro. In: Methods in Molecular Biology: Advanced Protocols in Oxidative Stress II. (pp.129-140).United States: Humana Press.
  • Toh, D., Yee, J., Koo, S., Murray, M., Lee, E. (2010), Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug metabolism and pharmacokinetics. 25(1), 112-119. [Abstract]


  • Rong, X., Li, Y., Ebihara, K., Zhao, M., Aini, W., Kusakabe, T., Hirata, M., Miyamoto, L., Murray, M., Nakao, K. (2009), An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice. The Journal of pharmacology and experimental therapeutics. 331(3), 1096-1103. [Abstract]
  • Chetty, M., d'Esposito, F., Zhang, W., Glen, J., Dore, G., Stankovic, Z., Edwards, R., Ramzan, I., Murray, M. (2009), In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation. British Journal of Clinical Pharmacology. 68(4), 574-579. [Abstract]
  • He, L., Qi, Y., Rong, X., Jiang, J., Yang, Q., Yamahara, J., Murray, M., Li, Y. (2009), The Ayurvedic medicine Salacia oblonga attenuates diabetic renal fibrosis in rats: suppression of angiotensin II/AT1 signaling. Evidence-based complementary and alternative medicine : eCAM. doi:10.1093/ecam/nep, 1-13. [Abstract]
  • Li, Y., Saito, Y., Kuwahara, K., Rong, X., Kishimoto, I., Harada, M., Adachi, Y., Nakanishi, M., Kinoshita, H., Horiuchi, M., Murray, M., Nakao, K. (2009), Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-mediated pro-hypertrophic signaling in the heart. Endocrinology. 150(8), 3759-65. [Abstract]
  • Xu, H., Murray, M., McLachlan, A. (2009), Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. Current drug metabolism. 10(6), 643-658. [Abstract]
  • Cui, P., Zhang, W., Hook, J., Tattam, B., Duke, C., Murray, M. (2009), Synthesis and NMR characterization of the methyl esters of eicosapentaenoic acid monoepoxides. Chemistry and physics of lipids. 159(1), 30-37. [Abstract]
  • Ghassabian, S., Chetty, M., Tattam, B., Chem, M., Glen, J., Rahme, J., Stankovic, Z., Ramzan, I., Murray, M., McLachlan, A. (2009), A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients. Therapeutic drug monitoring. 31(2), 239-246. [Abstract]